IP Library Granted Patent US 11,352,439
Granted Patent B2
US 11,352,439 · App. 15/358,395 · Granted Jun 7, 2022

Macrophage CAR (MOTO-CAR) in immunotherapy

Inventors: Kim Leslie O'Neill (Provo, UT); Scott Weber (Lindon, UT)
C07K16/40A61K35/15C07K14/57C07K14/705C07K14/70503C07K16/18C07K16/2866C07K16/30C12N5/0645C12Y204/02008C12Y207/01021A61K38/00A61K2039/505C07K2317/31C07K2317/622C07K2319/74C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,352,439
App. No.
15/358,395
Granted
Jun 7, 2022
Kind
B2
Abstract

Modified macrophage immune cells are provided for treatment of cancer and other diseases.

Claims (20)

1. A method for administering cells to a tumor in a subject, the method comprising:

administering to the subject human monocyte cells;

wherein the monocyte cells comprise a gene encoding a chimeric antigen receptor (CAR);

wherein the CAR comprises a fusion of an antigen binding antibody fragment and a TLR-4 cytoplasmic signaling domain, the cytoplasmic signaling domain polarizing the cells to M1 phenotype macrophages upon binding of the antibody fragment to its antigen.

2. The method according to claim 1 , wherein the antibody fragment is a single chain variable fragment (scFv).

3. The method according to claim 1 , wherein the antigen is HGPRT.

4. The method according to claim 2 , wherein the scFv is derived from a monoclonal antibody specific for an antigen expressed by cells of a cancer.

5. The method according to claim 1 , wherein the antigen is present on cells of a cancer.

6. The method according to claim 4 , wherein the monoclonal antibody is a human or mouse monoclonal antibody.

7. The method according to claim 1 , wherein the macrophages are stimulated by a co-stimulatory molecule.

8. The method according to claim 7 , wherein the co-stimulatory molecule is MD2 or CD14.

9. A method for administering cells to a tumor in a subject, the method comprising:

administering to the subject human monocyte cells;

wherein the monocyte cells comprise a gene encoding a chimeric antigen receptor (CAR);

wherein the gene encoding the CAR comprises a macrophage specific promoter;

wherein the CAR comprises a fusion of an antigen binding antibody fragment and a TLR-4 cytoplasmic signaling domain, the cytoplasmic signaling domain polarizing the cells to M1 phenotype macrophages upon binding of the antibody fragment to its antigen; and

wherein the antigen is TK1.

10. The method according to claim 1 , wherein the antigen is a salvage pathway enzyme.

11. The method according to claim 10 , wherein the salvage pathway enzymes is selected from the group consisting of TK1, HGPRT, DCK, and APRT.

12. The method according to claim 1 , wherein the gene encoding the CAR comprises a macrophage specific promoter.

Continuity (5)
Continuation PCTIB2016056140 · Oct 13, 2016
Continuation In Part 15236421 · Aug 13, 2016
Provisional Application 62240528 · Oct 13, 2015
Provisional Application 62204935 · Aug 13, 2015
Related Publication 20170166657A1 · Jun 15, 2017